WE ARE TARGETING PAIN AT ITS SOURCE

Virpax Pharmaceuticals specializes in developing novel and proprietary drug delivery systems across various pain indications in order to enhance compliance
and optimize the ability of each non-addictive product in our pipeline.

Our improved drug-delivery systems, and drug-releasing technologies are focused on advancing non-opioid and non-addictive pain management treatments allowing healthcare professionals to target a patient’s pain at its source. Our products cover a range of applications from postoperative pain to the treatment of acute and chronic pain.

Virpax has global rights to a proprietary patented Molecular Envelope Technology (MET) that uses an intranasal device to deliver enkephalin via nanoparticles for the management of acute and chronic pain, including pain associated with cancer.

Virpax has global rights to a patented metered-dose topical spray film delivery technology for musculoskeletal pain.

Virpax has worldwide rights to a patented injectable “local anesthetic” liposomal hydrogel technology for postoperative pain management.

non-opioid pain relief

Virpax® Pharmaceuticals is a publicly held company (Nasdaq: VRPX) located in Berwyn, PA and is focused on the development and commercialization of its non-addictive and neurological pipeline.

RECENT NEWS

VIEW MORE

NASDAQ:VRPX

Virpax Pharmaceuticals is now listed on the NASDAQ

Prescribers, regulators, and patients all seek non-addictive treatment options to combat the opioid epidemic. Virpax will utilize our drug delivery technologies to develop a pipeline of proprietary prescription candidates for commercialization.

OUR MISSION

Our mission is to improve widely used and newly developed non-addictive pain medicines, as well as neurological product candidates, by optimizing our proprietary delivery systems.

We want to provide healthcare professionals and patients with effective solutions to manage pain and neurological issues worldwide.

CalloutWE'RE WORKING TOIMPROVEPAIN MANAGEMENT

EXPERIENCED

EXECUTIVE LEADERSHIP

ROBUST

PIPELINE

REINVENTING PAIN RELIEF

CHANGING THE WAY WE MANAGE PAIN

Virpax’s proprietary pipeline is well positioned to meet the unmet needs in a multi-billion dollar market.

View our pipeline
Envelta Virpax Envelta blood brain barrier

Envelta™

Endogenous enkephalin intranasal spray

Envelta is being studied to manage acute and chronic pain, including pain associated with cancer, without the concerns of dependence, respiratory depression, and tolerance compared to morphine.

More about Envelta

Epoladerm™

Diclofenac metered-dose spray film

Epoladerm nonclinical studies have demonstrated improved drying times and less messy handling compared to topical gels/ointments. It’s an invisible application, therefore, more aesthetically appealing. Its pliable application allows for optimized use on joints and other contours of the body.

more about Epoladerm

Probudur™

Injectable long-acting bupivacaine hydrogel

Virpax will introduce its proprietary Probudur, a single injectable liposomal gel local anesthetic for postoperative pain management. Probudur will be the only liposomal gel bupivacaine with 96 hours of postoperative pain control; 24 hours longer than any other liposomal bupivacaine.

More about Probudur

AnQlar™ (MMS019)

High-density molecular masking spray

AnQlar is a high-density molecular masking intranasal spray, being developed as an anti-viral barrier to help prevent the risk of viral spread of SARS and influenza for up to 24 hours.

more about AnQlar
virpax pharma pain management mission

EXPLORE OUR

MISSION

new pain management solutions

DISCOVER OUR

PRODUCTS

Pain Management - Team

MEET OUR

TEAM

virpax pharmaceutical contact

LET’S

CONNECT